Echelon Fitness Announces Cyber Monday Flash Sale

Press release content from PR Newswire. The AP news staff was not involved in its creation.

CHATTANOOGA, Tenn., Nov. 30, 2020 /PRNewswire/ — Echelon Fitness is announcing a special, never before available, CYBER MONDAY FLASH SALE offering 25% OFF site-wide including equipment and accessories.

And for those ready to workout, Echelon’s immersive connected equipment is ready to ship. Customers who order on Cyber Monday can receive their products by Christmas.

Echelon offers connected bikes that give an immersive studio experience, smart rowers that take the rower down the best waterways in the world and reflect smart mirrors for personal training at the touch of a button. One Echelon membership allows up to five family members to enjoy all the benefits.

Two newest innovations include:

  • The smart Echelon Stride connected treadmill, with access to thousands of daily live and on-demand studio level classes with our world class instructors, easy set up and storage, built in wheels and a slim ten-inch-deep profile when folded.
  • Echelon’s limited edition Connect EX-1 LE in matte grey.The EX-1 LE offers sleek, aesthetic appeal while remaining equipped with the functionality necessary for effective rides for years to come.

There’s no better time to buy Echelon’s connected equipment! Details on offer, equipment and benefits of membership can be found at https://echelonfit.com/. **Memberships not included in the discount offer.

ABOUT ECHELON FITNESS

Echelon Fitness has been revolutionizing at-home connected fitness since deputing its first Connect Bike in 2017. What began as a mission to make healthy living attainable and accessible to all evolved into a line of innovative fitness solutions—as well as a thriving community. Ranging from sophisticated indoor cycling bikes, to touch-screen fitness mirrors and more, every product boasts thoughtful design and state-of-the-art technology, enabling people to exercise how they want, when they want and with who they want. By leveraging The Echelon Fit App and United Membership, members gain access to a variety of live and on-demand classes led by down-to-earth fitness instructors. Members can also use the app to track their performance against Echelon’s live leaderboard and overall progress, all while enjoying some healthy competition. For more information, visit https://echelonfit.com/.

View original content to download multimedia: http://www.prnewswire.com/news-releases/echelon-fitness-announces-cyber-monday-flash-sale-301181667.html

SOURCE Echelon Fit

Source Article

Read more

Lobe Sciences Announces Launch of Preclinical Study in Collaboration with the University of Miami Miller School of Medicine

(MENAFN – Newsfile Corp) Lobe Sciences Announces Launch of Preclinical Study in Collaboration with the University of Miami Miller School of Medicine

Vancouver, British Columbia–(Newsfile Corp. – November 30, 2020) – Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (” Lobe ” or the ” Company “) is pleased to announce the launch of preclinical research studies using psilocybin and N-Acetylcysteine (” NAC “) for the treatment of mild traumatic brain injury/concussion (” mTBI “) with post-traumatic stress disorder (” PTSD “). The study is in collaboration with a multidisciplinary team of scientists and physicians at the University of Miami Miller School of Medicine under the lead of Michael E. Hoffer, M.D., professor of otolaryngology and neurological surgery.

NAC has been shown to be safe and efficacious in a phase I human clinical study in treating military personnel who had suffered mTBI. The initial research focus is to demonstrate the safety and efficacy of the combination of psilocybin and NAC using broadly accepted rodent models. Final results are expected in 2021. Once this is established, more specific work can examine dose response, medicine uptake, and medicine levels. The research team at the Miller School of Medicine has conducted prior studies involving NAC with mTBI and has a license from the United States Drug Enforcement Administration to conduct research using Schedule I controlled substances, which includes psilocybin.

The Miller School of Medicine is an internationally recognized leader in medical research, ranked No. 39 among the top medical schools in the nation by Blue Ridge Institute for Medical Research. In 2019, the medical school submitted 1,968 research proposals and was awarded $149 million in research funding from the National Institutes of Health (NIH).

Advances in neuro-diagnostic assessment have revealed mild traumatic brain injury (concussion) is more common than previously thought and potentially associated with a host of negative health outcomes. The Centers for Disease Control (” CDC “) estimates that there are 3 million emergency room visits and over 230,000 hospitalizations due to TBI in any given year in the United States alone. Also, at the same time there are 5.3 million Americans living with the effects of mTBI (a 53% increase over ten years ago). The World Health Organization calls traumatic brain injury a “silent epidemic” that affects over 70 million individuals across the world. The United States Department of Defense estimates that over 345,000 individuals are affected by mTBI and that 20% of all service members who deploy suffer mTBI. mTBI and PTSD are significant health care issues that often co-occur and impact each other.

Dr. Hoffer, the principal investigator on the study, said, “This a very important extension of our work with NAC and other medicines to identify new treatments for mTBI and PTSD. We are hopeful that this new combination of psilocybin with NAC will lead us to better solutions for those suffering from mTBI and/or PTSD.”

Maghsoud Dariani, Chief Science Officer of Lobe said, “We are very excited to begin the preclinical studies in collaboration with Dr.

Read more

Ionis announces AstraZeneca’s initiation of the Phase 2b clinical study of its antisense medicine targeting PCSK9 to lower LDL-cholesterol

CARLSBAD, Calif., Nov. 30, 2020 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that the biopharmaceutical company AstraZeneca has initiated a Phase 2b clinical trial of ION449 (AZD8233), an investigational antisense medicine designed to reduce blood cholesterol levels in patients with dyslipidemia by targeting proprotein convertase subtilisin/kexin type 9 (PCSK9), an important regulator of low-density lipoprotein cholesterol (LDL-C). PCSK9 is an enzyme that controls the number of LDL receptors on the surface of cells. People with genetic variations that reduce PCSK9 function have lower LDL-C levels in the blood and a lower risk for major cardiovascular events. ION449 is a LIgand Conjugated Antisense (LICA) medicine being developed by AstraZeneca as part of a collaboration between Ionis and AstraZeneca.


(PRNewsfoto/Ionis Pharmaceuticals, Inc.)

The Phase 2b, randomized, double-blind, placebo-controlled trial will enroll approximately 108 participants, aged 18-75, who have LDL-C levels between 70 and 190 mg/dL and are receiving moderate- or high-intensity statin therapy as defined by the American College of Cardiology/American Heart Association (ACC/AHA) guidelines on blood cholesterol management. The primary objective is to assess the effect of different doses of ION449 on LDL-C compared to placebo at Week 12 in patients taking baseline statin therapy.  The study will evaluate three dose levels of ION449 versus placebo, all administered once a month by subcutaneous injection. Safety and tolerability will be evaluated along with a number of secondary endpoints. Learn more about the trial at: https://clinicaltrials.gov/ct2/show/NCT04641299. 

In a Phase 1 study reported at the American Heart Association (AHA) Scientific Sessions on November 13, single subcutaneous doses of ION449 (AZD8233) demonstrated dose-dependent mean reductions in circulating plasma PCSK9 and LDL-C levels of >90 percent and up to 70 percent, respectively, in subjects who had a baseline LDL-C between 100 and 190 mg/dL without concomitant statin therapy.Doses up to 120 mg were evaluated. ION449 was observed to be safe and well-tolerated at all dose levels. 

“Results from the Phase 1 study showed that ION449 potently reduces PCSK9 and LDL cholesterol. ION449 demonstrated best-in-class potential for PCSK9 inhibition and LDL-C reduction, supporting larger clinical trials that are now underway to further evaluate efficacy and safety,” said Sotirios “Sam” Tsimikas, M.D., senior vice president, clinical development and cardiovascular franchise leader at Ionis. “The growing evidence supporting Ionis’ advanced LICA technology in cardiovascular disease holds promise for more effective approaches to lower LDL-C and to address cardiovascular disease, the leading cause of death worldwide.”

Dr. Tsimikas will provide an update on Ionis’ cardiovascular programs during Ionis’ Virtual Investor Day, Dec. 7, 2020, beginning at 12 p.m. EST.

Ionis earned a milestone payment of $20 million from AstraZeneca for the Phase 2b clinical trial initiation of ION449. Ionis and AstraZeneca are collaborating on potential treatments for kidney disease, cardiometabolic disease and cancer.

About Ionis Pharmaceuticals, Inc.

As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, drug discovery platform called antisense technology that can treat diseases where no other therapeutic approaches have proven effective. Our drug

Read more

Winnipeg Dental Practice Announces The Addition Of A New Dentist To The Company As They Continue To Grow & Expand – Press Release

Winnipeg Dental Practice Announces The Addition Of A New Dentist To The Company As They Continue To Grow & Expand

East Kildonan Dental Group, a fast-growing dental practice, is delighted to announce the addition of a new dentist to their ever-expanding team. The new dentist Dr. Ji Hun Han was born in Seoul, South Korea, and then moved to Winnipeg in 1998. He completed his D.M.D at the University of Manitoba Faculty of Dentistry in 2020 and his Bachelor of Science in Dentistry [B.Sc. (DENT)] with research on nanoparticles and their use in dentistry.

WINNIPEG, Canada East Kildonan Dental Group, a fast-growing dental practice, is delighted to announce the addition of a new dentist to their ever-expanding team. The new dentist Dr. Ji Hun Han was born in Seoul, South Korea, and then moved to Winnipeg in 1998. He completed his D.M.D at the University of Manitoba Faculty of Dentistry in 2020 and his Bachelor of Science in Dentistry [B.Sc. (DENT)] with research on nanoparticles and their use in dentistry.  

Although he enjoys all aspects of general dentistry, his driving passion is in the education of patients, with the aims of improving their oral health and preventing potential disease progression. He acknowledges that dental anxiety is a huge issue for many patients and has devised a range of strategies to help patients overcome their worries and concerns. He is interested in building a relationship with his patients so that they feel comfortable at their dental appointments, and is constantly working to improve his dental skills and knowledge through continuing education courses. Outside of his work, he enjoys rock climbing, playing soccer, and watching movies in his spare time. He is also fluent in English and Korean. 

“We are thrilled to have Dr. Han on our team, and we know that he will be a valuable asset to the business,” said dental colleague, Alex Serebnitski. “Dr. Han stood out from the crowd, has an excellent work ethic, and also demonstrates compassion and a nurturing attitude, which reflects our business ethos. We look forward to working with him for many years to come.” 

East Kildonan Dental is a locally owned and operated business in Winnipeg, Manitoba. The dental office was initially established in 1949, and over the years, has become a staple in East Kildonan. They take pride in the quality and variety of dental services they’ve offered to many friends and families over the years. 

With the addition of Dr. Han, East Kildonan Dental Group is extending its hours of operation. They can see more patients because of the new dentist. This business is continually working to serve the people of Winnipeg better, and their practice is now more accessible thanks to their growing team.

The new hours are Monday to Thursday, from 8 AM – 8 PM, and Friday to Saturday from 8:30 AM – 4:30 PM.

For more information about the company and the various dental services that they provide, visit their website at https://ekdentalgroup.com/.

https://www.ekdentalgroup.com/news/winnipeg-dental-practice-announces-addition-new-dentist-company-they-continue-grow-expand

https://local.google.com/place?id=5349875352996246164&use=posts&lpsid=3119218641341562462

https://g.page/EastKildonanDental?share

 

Media Contact
Company Name: East Kildonan Dental Group
Contact Person: Alex Serebnitski
Email: Send Email
Phone: 204-661-2614
Address:807 Henderson

Read more

Ionis announces third investigational antisense medicine to treat nonalcoholic steatohepatitis (NASH) enters development

CARLSBAD, Calif., Nov. 23, 2020 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that the biopharmaceutical company AstraZeneca has licensed ION455, an investigational antisense medicine being developed as a potential treatment for nonalcoholic steatohepatitis (NASH). ION455 is the second medicine for the treatment of NASH that Ionis has partnered with AstraZeneca. The companies have also partnered on ION839 (AZD2693), which is designed to inhibit the production of patatin-like phospholipase domain-containing 3 (PNPLA3) protein, a major genetic determinant of NASH progression. Separately, Ionis is also developing a wholly owned NASH program. ION224 is designed to reduce the production of DGAT2, or diacylglycerol acyltransferase 2, for treating patients with NASH. ION224 is one of more than 20 medicines in the growing Ionis-owned pipeline that the company is prioritizing and preparing for commercialization.

NASH is the most severe form of nonalcoholic fatty liver disease (NAFLD). It is related to the epidemic of obesity, pre-diabetes and diabetes. Unlike liver disease caused by alcohol consumption, NAFLD is the result of an accumulation of fat in the liver, which can lead to inflammation and cirrhosis, an advanced scarring of the liver that prevents the liver from functioning normally. About 20 percent of NASH patients are reported to develop cirrhosis and 30 to 40 percent of patients with NASH cirrhosis experience liver-related death.i Currently, a liver transplant is the only treatment for advanced cirrhosis and liver failure. Because of the high prevalence of NASH, it has recently become the third most common indication for liver transplantation in the U.S.

“Today, there are no FDA-approved medicines to specifically treat nonalcoholic steatohepatitis. However, due in large part to the progress made by our cardio-metabolic franchise, three Ionis-discovered novel medicines are now in development. These are encouraging advances that we hope will one day bring therapeutic benefit to patients who have limited treatment options,” said Brett P. Monia, Ph.D., Ionis’ chief executive officer. 

ION455 is the fourth medicine to reach development in partnership with AstraZeneca. Ionis earned $30 million from AstraZeneca for licensing ION455 and is eligible to earn up to $300 million in milestone payments plus royalties on net sales. AstraZeneca will have responsibility for further development of ION455, including regulatory filings, and commercialization.

In addition to NASH, Ionis and AstraZeneca are collaborating on potential treatments for kidney disease, cardiovascular disease and cancer.

Ionis’ Forward-looking Statement

This press release includes forward-looking statements regarding Ionis’ business and the therapeutic and commercial potential of ION455, ION839 (AZD2693), ION224 and Ionis’ technologies and products in development. Any statement describing Ionis’ goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, including those related to the impact COVID-19 could have on our business, and including but not limited to those related to our commercial products and the medicines in our pipeline, and particularly those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for

Read more

The Alliance for Regenerative Medicine Announces Record Sector Financing in 2020

The regenerative medicine sector attracted $15.9 billion in financing through just the first three quarters of the year, shattering the previous record of $13.5 billion

Washington, DC – ( NewMediaWire ) – November 19, 2020 – Global financing for the regenerative medicine and advanced therapy sector set an annual record of $15.9 billion through just the first three quarters of 2020, according to  data  released today by the Alliance for Regenerative Medicine (ARM), the leading international advocacy organization dedicated to realizing the promise of regenerative medicines.

Despite the COVID-19 pandemic, financing for the cell, gene, and tissue-based therapies sector surpassed the previous record of $13.5 billion set during full-year 2018.

“There is strength across all types of investment and stages of the pipeline, from early-stage cell-based immuno-oncology to late-stage gene therapies,” said Janet Lambert, CEO of ARM. “The outlook for patients has never been brighter.”

Investors remain bullish about the promise of profound, durable, and possibly curative regenerative medicines to treat a range of diseases and disorders.

Public financing continues to drive the sector, through both IPOs ($2.8 billion YTD) and follow-on financings ($5.7 billion YTD). At $4.1 billion year-to-date, venture capital financing is also on track to surpass the previous record of $4.3 billion set in 2019.

“The rapid advancement of the science behind regenerative medicine makes this a very dynamic time for investors and a hopeful time for patients,” said Jason Rhodes, a partner at Atlas Venture. “The breadth of approaches now available — from CRISPR to CAR-Ts to lentiviruses and non-viral gene therapies — enables us to pick the right tool for the specific biology that we’re addressing.”

Highlights from ARM’s third-quarter 2020 data include:

Gene therapy financing was $3.5B in Q3 2020 and $12 billion YTD, up 178% and 114% from 2019 levels respectively; cell therapy financing reached $3 billion in Q3 2020 and $11 billion YTD, up 97% and 242%, respectively; tissue-based therapy financing was $226 million in Q3 2020 and $311 million YTD, up 11% and 311% respectively.*

At the end of Q3 2020, there were 1,109 regenerative medicine clinical trials ongoing worldwide – 373 in gene therapy, 492 in cell-based immuno-oncology, 202 in cell therapy, and 42 in tissue-based therapies.

Of the 1,109 clinical trials, 388 target more prevalent diseases, including prevalent cancers (159), cardiovascular disease (35), diseases of the central nervous system (33), infectious diseases including COVID-19 (38), and diabetes (17).

There are 97 ongoing Phase 3 clinical trials, with regulatory decisions expected in the coming months in the US and Europe for several product candidates across cell, gene, and tissue-based therapies; cell-based immuno-oncology now comprises more than half of the 418 Phase 1 trials.

There are 1,026 regenerative medicine and advanced therapy developers active globally, up from 1,001 in our previous report covering the first half of 2020. Of the current total, 536 are active in gene therapy, 641 are active in cell therapy, and 135 are active in tissue-based therapies.

* Some companies utilize multiple technology types, and financings for

Read more

Optum Ireland announces Healthcare Scholars and support for Ulster’s new School of Medicine

Optum Ireland has announced its annual Optum Healthcare Scholars and a commitment to funding two dedicated scholarships for the new graduate entry School of Medicine at Ulster University.

Optum Healthcare Scholars benefit from annual financial assistance, as well as other support they may require, to complete their undergraduate studies. The program, established in 2018, is designed to support students in County Donegal from less advantaged backgrounds who may face additional challenges.

The newly appointed Healthcare Scholars are:

Moya McCloskey (Crana College)
Caitlín Gillespie (St Columba’s Stranorlar)
Saoirse Bonner (Rosses Community School)
Artur Kryszkowski (St Eunan’s College)
Siobhán Griffin (St Columba’s Stranorlar)

The scholars join the existing cohort of Healthcare Scholars from County Donegal. All scholars selected for the program are studying healthcare and innovative technology programs in Letterkenny Institute of Technology, Ulster University and National University of Ireland, Galway.

CEO of Optum Ireland, Padraig Monaghan said:

“Optum has a presence in the North West for more than 20 years. Our scholarship program is designed to meet the needs and realities of this cross-border region and support the local healthcare system. We are delighted that our contribution comes at a time when there is an acute focus on the healthcare service and an increased level of application to third level healthcare courses in Ireland”.

The establishment of a new, graduate entry School of Medicine in Ulster University’s Magee campus in Derry city is a significant development for the North West City region. Optum has announced that the scholarship program will support two graduate medical students when the School of Medicine opens in 2021.

The Foundation Dean of the School of Medicine, Professor Louise Dubras, has welcomed the funding announcement for prospective students:

‘Ulster University is a proud partner of Optum Ireland and their commitment to fund postgraduate scholarships comes at a critical time for the School of Medicine and is most welcome. Our new medical provision will provide much-needed doctors for the North West’

Sophie Carlin, a third year Personalised Medicine student at Ulster University, received an Optum Healthcare Scholarship in 2018. She is now being supported by Optum during her placement year.

Sophie was selected by Dr. Kyle Matchett, Lecturer in Molecular Immunobiology, to be a member of his research team focusing on an aggressive childhood leukaemia. The research aims to better understand how childhood leukaemia develops including the role of the key altered gene and to create more effective, kinder treatments.

Sophie hopes to become a Doctor in Cancer Research and help people who have been affected by cancer,

“Optum Ireland has made us a part of their family and I will be forever grateful to them for giving me this scholarship and allowing me to pursue my dreams.”

Source Article

Read more

Shore Capital Partners Announces Founding of Southern Sports Medicine Partners

Strategic Partnership with Jaffe Sports Medicine Includes Four Locations in West Florida

Shore Capital Partners (“Shore”), a private equity firm, is pleased to announce it has founded Southern Sports Medicine Partners (“SSMP”), through the completion of a strategic partnership with Jaffe Sports Medicine (“JSM”). SSMP provides interventional pain management practices with administrative support, so physicians can focus on delivering the highest quality of patient care.

JSM, led by founder Dr. Peter Jaffe, provides patient-centric care at four locations in the Naples, FL area. Mike Cooper, a founding partner of Shore, commented, “We are thrilled to partner with Dr. Jaffe. He is one of the most respected and well-known physicians in West Florida. Having built a world-class practice, Dr. Jaffe shares our vision to deliver clinical excellence at greater scale.”

Dr. Jaffe said, “I partnered with Shore for their track record of transformational growth in healthcare and a shared belief in what it will take to be the leading interventional pain management platform in the Southeast. As healthcare continues to become more retail and consumer-oriented, the time is ideal to embrace growth, patient experience, and best in class programs and options for physicians in all stages of their careers. Southern Sports Medicine Partners is off to a great start and I have high aspirations for what we can achieve.”

SSMP will grow its platform across the region by investing in people and processes to support the operations, finance, accounting, marketing, human resources, and IT functions at affiliated practices, thereby allowing physicians to focus on clinical excellence and serving their communities. SSMP will pursue affiliations with independent interventional pain management practices to build a network of top clinicians in a physician-led culture.

“We are building a leader of scale in pain management and sports medicine, starting with Dr. Jaffe and his team,” said Mr. Cooper. “We are well-positioned to support the continued transition to consumer-directed healthcare, while maintaining the physician’s role and clinical expertise as the most critical aspect of treatment. Additionally, Shore has helped to bring together an exceptional board of directors consisting of industry thought leaders and physicians alike to guide our strategy and growth plan.”

SSMP represents the third platform investment out of Shore Capital Partners Fund III, L.P., a $293 million investment vehicle raised in April 2019.

To learn more about Jaffe Sports Medicine, please visit www.jaffesportsmedicine.com.

About Shore Capital

Shore Capital Partners is a Chicago-based private equity firm focused on microcap Healthcare and Food and Beverage investments. Shore supports management partners with capital, business development expertise, and industry knowledge to accelerate growth, fund acquisitions, and generate value to shareholders. Shore targets investments in proven, successful private companies with superior management teams, stable cash flow, and significant growth potential, including organic and growth through industry consolidation. Shore has $1.1 billion of equity capital under management through various investment vehicles. For more information on Shore, please visit www.shorecp.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201102005029/en/

Contacts

Adam Werder
Shore Capital
(312) 348-7580
https://www.linkedin.com/company/shore-capital-partners/

Source Article

Read more

Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Clinical Trials of Setmelanotide in The Lancet Diabetes & Endocrinology

Largest studies in POMC and LEPR deficiency obesities demonstrate that treatment with setmelanotide reduced body weight and hunger

BOSTON, Oct. 30, 2020 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, announced today that results from two pivotal Phase 3 studies evaluating setmelanotide in proopiomelanocortin (POMC) deficiency obesity and leptin receptor (LEPR) deficiency obesity were published in The Lancet Diabetes & Endocrinology. As previously reported, data from the studies demonstrate that treatment with setmelanotide, the company’s melanocortin-4 receptor (MC4R) agonist, led to statistically significant and clinically meaningful reductions of weight and hunger.

“Results from Rhythm’s pivotal Phase 3 studies, which are the largest studies to date in POMC and LEPR deficiency obesities, provide evidence regarding the safety and efficacy of setmelanotide and we believe they validate its potential long-term use as a novel treatment for severe obesity and hyperphagia,” said co-author Peter Kühnen, M.D., Institute for Experimental Pediatric Endocrinology, Charité Universitätsmedizin Berlin, Germany. “It is important to recognize the signs of these rare genetic disorders because we may soon have a targeted treatment option available for the first time for obesity disorders caused by impairments of the MC4R pathway.”

Rhythm initially reported positive topline data from the Phase 3 studies in August 2019 and subsequently presented updated data in a late-breaking research forum during the 37th Annual Meeting of The Obesity Society at ObesityWeek® 2019.

Eight of 10 participants with POMC deficiency obesity (80%; P<0.0001 compared with historical data) and five of 11 participants with LEPR deficiency obesity (45%; P=0.0001 compared with historical data) achieved at least 10 percent weight loss at approximately one year. The mean percent change in “most hunger” score in participants aged 12 years and older was -27.1 percent (n=7; P=0.0005) in POMC deficiency obesity and -43.7 percent (n=7; P<0.0001) in LEPR deficiency obesity. Consistent with prior clinical experience, setmelanotide was generally well-tolerated in both trials. The most common adverse events were injection site reaction, skin hyperpigmentation, and nausea.

“These results are significant because, as we know from natural history data, individuals living with POMC or LEPR deficiency obesity consistently experience substantial weight gain each year beginning in early childhood, and we would not expect any of these patients to be able to achieve 10 percent weight loss over the course of a year without continued treatment,” said co-author Karine Clément, professor of nutrition at Pitié-Salpêtrière hospital and Sorbonne University in Paris. “These data and the significant unmet need to address the obesity and hyperphagia caused by rare genetic disorders of obesity underscore the importance of testing for genetic variants that may impair MC4R activation and lead to severe obesity.”

In May 2020, Rhythm announced that the U.S. Food and Drug Administration (FDA) accepted the company’s New Drug Application (NDA) for setmelanotide for the treatment of POMC deficiency obesity and LEPR deficiency obesity, granted Priority Review of the NDA and assigned a Prescription Drug

Read more

Synaptive Medical Announces Close of $17M Preferred Share Financing

Funding to advance Synaptive’s suite of fully automated cranial and spinal equipment and software designed to optimize personalized patient care

TORONTO, Oct. 29, 2020 (GLOBE NEWSWIRE) — Synaptive Medical, a leader in automation and robotics, announced today it has completed a sale of preferred equity totaling $17,000,000 USD. The investment was made by Sensegain Group, a leading asset management firm in China. Ms. Jing Yang, Board Member & Senior Partner of Sensegain, will join Synaptive’s Board of Directors.

Sensegain Group is headquartered in Beijing with multiple locations globally and has developed a strong partnership with industry leaders, as well as deep insights into sectors including TMT, Healthcare, and Advanced Manufacturing in China, United States, Canada, Israel, and other countries. Sensegain maintains a value investment principle and “Global + China” beliefs that help to maximize the value of portfolio companies and partners internationally. Synaptive management team worked tightly with Sensegain Group international team and the two parties are of great confidence that this investment will serve as a bright start of a long-term collaboration with each other.

This funding will enable Synaptive to further expand the availability of its suite of fully automated and integrated hardware and software products that enhance healthcare providers’ capabilities in diagnostic imaging, as well as surgical planning, navigation and visualization in the neurological and orthopedic spaces. Synaptive’s products have been uniquely designed to optimize workflow and enhance medical decision-making to improve patient outcomes.

In addition, Synaptive is announcing a new distribution partnership with Cicel Science and Technology Company, Ltd. of Beijing, for entry into the China market.

Marc Buntaine, CEO of Synaptive Medical, stated, “This investment is a testament to the confidence new investors have in Synaptive’s mission to provide state-of-the-art products that enable surgeons and healthcare professionals to provide safer patient-specific care in highly delicate cranial or spinal procedures for neurological disorders or injuries each year. With this financing, we are further committed to broadening the availability of our product offering to enter the greater China market with our new partner, Cicel.”

Cameron Piron, president and co-founder of Synaptive Medical, added, “We are excited to bring a new board member to our group with a strong background in finance and the China market.”

Synaptive offers products which provide world-class MRI cranial imaging, enhanced surgical planning, visualization both before and during surgery, and efficient data management throughout the clinical workflow, including medical informatics AI research. Synaptive’s products are modular and designed for seamless integration both within the Synaptive suite and with other products, so hospitals may purchase Synaptive offerings either individually or together, to best suit their needs.

About Synaptive Medical

Synaptive Medical Inc., a Toronto-based, global medical device and technology company solves surgical, imaging, and data challenges to improve the quality of human lives. Synaptive’s integrated suite of products – bridging MRI, surgical planning, navigation, and robotic visualization – delivers novel information with automated efficiency across all stages of clinical intervention.

About Sensegain Group

Sensegain Group is a leading asset management group headquartered

Read more